Apellis Pharmaceuticals (APLS) – Guidance
-
Apellis Pharmaceuticals (APLS) Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
-
Apellis Pharmaceuticals (APLS) Reports Prelim Q3 US Sales of SYFOVRE of $74M
Back to APLS Stock Lookup